Back to section
Go to the discussion
Heaney M L, Gardner J R, Karasavvas N, Golde D W, Scheinberg D A, Smith E A, O’Connor O A, Vitamin C antagonizes the cytotoxic effects of antineoplastic drugs, Cancer Res, 68 (19), 2008, 8031–8038.
Chegaev K, Riganti C, Rolando B, Lazzarato L, Gazzano E, Guglielmo S, Ghigo D, Fruttero R, Gasco A, Doxorubicin-antioxidant co-drugs, Bioorganic & Medicinal Chemistry Letters, 23 (19), 2013, 5307–5310.
Jamison J M, Gilloteaux J, Taper H S, Calderon P B, Perlaky L, Thiry M, Neal D R, Blank J L, Clemens R J, Getch S, Summers J L, The In Vitro and In Vivo Antitumor Activity of Vitamin C: K3 Combinations Against Prostate Cancer, Nova Science Publishers, 2005, 189-236.
Kang Y, Park M A, Heo S W, Park S Y, Kang K W, Park P H, Kim J A, The radio-sensitizing effect of xanthohumol is mediated by STAT3 and EGFR suppression in doxorubicin-resistant MCF-7 human breast cancer cells, Biochimica et Biophysica Acta (BBA) - General Subjects, 1830 (3), 2013, 2638–2648.
Kurbacher C M, Wagner U, Kolster B, Andreotti P E, Krebs D, Bruckner H W, Ascorbic acid (vitamin C) improves the antineoplastic activity of doxorubicin, cisplatin, and paclitaxel in human breast carcinoma cells in vitro, Cancer Letters, 103 (2), 1996, 183–189.
Lal S, Mahajan A, Chen W N, Chowbay B, Pharmacogenetics of target genes across doxorubicin disposition pathway: a review, Curr Drug Metab, 11 (1), 2010, See comment in PubMed Commons 115-28.
Ludke A R, Sharma A K, Akolkar G, Bajpai G, Singal P K, Downregulation of vitamin C transporter SVCT-2 in doxorubicin-induced cardiomyocyte injury, American Journal of Physiology - Cell Physiology, 303 (6), 2012b, 645-53.
Niedzwiecki A, Rath M, Clinical Nutrients in Cancer Therapy: A Scientific Review and Perspective. Dr. Rath Research Institute, 2005.
Prados J, Melguizo C, Rama A R, Ortiz R, Segura A, Boulaiz H, Vélez C,Affiliated withDepartment of Human Anatomy and Embryology, School of Medicine, Institute of Biopathology and Regenerative Medicine (IBIMER), University of Granada Caba O, Ramos J L, Aránega A, Gef gene therapy enhances the therapeutic efficacy of doxorubicin to combat growth of MCF-7 breast cancer cells, Cancer Chemotherapy and Pharmacology, 66 (1), 2010, 69-78.
Shimpo K, Nagatsu T, Yamada K, Sato T, Niimi H, Shamato M, Takeuchi T, Umezawa H, Fujita K, Ascorbic acid and adriamycin toxicity, American Journal of Clinical Nutrition, 54 (6), 1991, 1298-1301.
Venturelli S, Sinnberg T W, Berger A, Noor S, Levesque M P, Böcker A, Niessner H, Lauer U M, Bitzer M, Garbe C, Busch C, Epigenetic Impacts of Ascorbate on Human Metastatic Melanoma Cells, Front Oncol, 4: 227, 2014, 10.3389/fonc.
Verrax J, Calderon P B, The controversial place of vitamin C in cancer treatment, Biochemical pharmacology, 76 (12), 2008, 1644–52.
Vilela- Miranda A L, Grisolia C K, Longo J P, Peixoto R C, de Almeida M C, Barbosa L C, Roll M M, Portilho F A, Estevanato L L, Bocca A L, Báo S N, Lacava Z G, Oil rich in carotenoids instead of vitamins C and E as a better option to reduce doxorubicin-induced damage to normal cells of Ehrlich tumor-bearing mice: hematological, toxicological and histopathological evaluations, The Journal of Nutritional Biochemistry, 25 (11), 2014, 1161- 1176.
Spojenie nekonvenčnej nutričnej terapie vitamínu C s doxorubicínom na podporu protinádorovej aktivity
Go to the discussion
Spojenie nekonvenčnej nutričnej terapie vitamínu C s doxorubicínom na podporu protinádorovej aktivity
Natália Antoliková 1 Ivan Talian 2 Peter Bober 2 Zuzana Tomková 2 Martina Chripková 1 Ján Sabo 2
1Univerzita veterinárskeho lekárstva a farmácie v Košiciach, Košice, SR
2Ústav lekárskej a klinickej biofyziky, Univerzita Pavla Jozefa Šafárika v Košiciach
natalia.antolikova@uvlf.sk
2Ústav lekárskej a klinickej biofyziky, Univerzita Pavla Jozefa Šafárika v Košiciach
Nádorové ochorenie predstavuje najčastejšiu príčinu úmrtia na celom svete, a to aj napriek neustálym pokrokom vo výskumnej a vývojovej oblasti. V experimentálnych terapeutických postupoch sa do popredia dostáva nutričná terapia s preukázateľnou schopnosťou minimalizovať škodlivý vplyv oxidačného stresu získaného pôsobením tradičnej chemoterapie či rádioterapie. Jednou zo skúmaných možností pre pacientov s diagnostikovaným karcinómom je parenterálna aplikácia vitamínu C známeho ako antioxidant, avšak v poslednej dobe sa deklarujú aj jeho prooxidačné- protinádorové účinky. V tejto štúdii sme sa zamerali na liečbu pokročilého karcinómu prsníka kombináciu doxorubicínu ako klasického a zároveň najúčinnejšieho chemoterapeutika v tejto indikácií s vitamínom C. Výsledky naznačujú potenciálny synergický antiproliferatívny účinok stanovený na bunkových líniách MCF-7 za použitia analyzátora RTCA. Bunky rakoviny prsníka boli vystavené rôznym koncentráciám vitamínu C (10 µM - 700 µM) spoločne s 1 µM doxorubicínom. Najnižšie koncentrácie (10 µM) vitamínu C s 1 µM doxorubicínom potvrdili antioxidačné pôsobenie askorbátu, inhibíciu rastu nádorových buniek preukázala koncentrácia 100 µM vitamínu C a 1 µM doxorubicínu, najvyššie koncentrácie (700 µM) vitamínu C s 1 µM doxorubicínom reprezentovali vysoký cytotoxický účinok na MCF-7 bunkové línie.
ITMS: 26220120067 and by VEGA 1/0103/16.
- Alfaro Y, Delgado G, Cárabez A, Anguiano B, Aceves C, Iodine and doxorubicin, a good combination for mammary cancer treatment: antineoplastic adjuvancy, chemoresistance inhibition, and cardioprotection, Mol Cancer, 12, 2013, 10.1186/1476-4598-12-45.
Crozier J A, Swaika A, Moreno-Aspitia A, Adjuvant chemotherapy in breast cancer: To use or not to use, the anthracyclines, World J Clin Oncol, 5 (3), 2014, 529–538.
Duconge J, Miranda- Massari J R, Gonzalez M J, Jackson J A, Warnock W, Riordan N H, Pharmacokinetics of Vitamin C: insights into the oral and intravenous administration of ascorbate, P R Health Sci J, 27 (1), 2008, 7-19.
Frei B, Lawson S, Vitamin C and cancer revisited, Proc. Natl. Acad. Sci. USA, 105 (32), 2008, 11037–11038.
Friedrichs K, Hölzel F, Jänicke F, Combination of taxanes and anthracyclines in first-line chemotherapy of metastatic breast cancer, European Journal of Cancer, 38 (13), 2002, 1730–1738.
Ghosh S K, Yigit M V, Uchida M, Ross A W, Barteneva N, Moore A, Medarova Z, Sequence-dependent combination therapy with doxorubicin and a survivin-specific small interfering RNA nanodrug demonstrates efficacy in models of adenocarcinoma, Int J. Cancer, 134 (7), 2014, 1758–1766.
Heaney M L, Gardner J R, Karasavvas N, Golde D W, Scheinberg D A, Smith E A, O’Connor O A, Vitamin C antagonizes the cytotoxic effects of antineoplastic drugs, Cancer Res, 68 (19), 2008, 8031–8038.
Chegaev K, Riganti C, Rolando B, Lazzarato L, Gazzano E, Guglielmo S, Ghigo D, Fruttero R, Gasco A, Doxorubicin-antioxidant co-drugs, Bioorganic & Medicinal Chemistry Letters, 23 (19), 2013, 5307–5310.
Jamison J M, Gilloteaux J, Taper H S, Calderon P B, Perlaky L, Thiry M, Neal D R, Blank J L, Clemens R J, Getch S, Summers J L, The In Vitro and In Vivo Antitumor Activity of Vitamin C: K3 Combinations Against Prostate Cancer, Nova Science Publishers, 2005, 189-236.
Kang Y, Park M A, Heo S W, Park S Y, Kang K W, Park P H, Kim J A, The radio-sensitizing effect of xanthohumol is mediated by STAT3 and EGFR suppression in doxorubicin-resistant MCF-7 human breast cancer cells, Biochimica et Biophysica Acta (BBA) - General Subjects, 1830 (3), 2013, 2638–2648.
Kurbacher C M, Wagner U, Kolster B, Andreotti P E, Krebs D, Bruckner H W, Ascorbic acid (vitamin C) improves the antineoplastic activity of doxorubicin, cisplatin, and paclitaxel in human breast carcinoma cells in vitro, Cancer Letters, 103 (2), 1996, 183–189.
Lal S, Mahajan A, Chen W N, Chowbay B, Pharmacogenetics of target genes across doxorubicin disposition pathway: a review, Curr Drug Metab, 11 (1), 2010, See comment in PubMed Commons 115-28.
Ludke A R, Sharma A K, Akolkar G, Bajpai G, Singal P K, Downregulation of vitamin C transporter SVCT-2 in doxorubicin-induced cardiomyocyte injury, American Journal of Physiology - Cell Physiology, 303 (6), 2012b, 645-53.
Niedzwiecki A, Rath M, Clinical Nutrients in Cancer Therapy: A Scientific Review and Perspective. Dr. Rath Research Institute, 2005.
Prados J, Melguizo C, Rama A R, Ortiz R, Segura A, Boulaiz H, Vélez C,Affiliated withDepartment of Human Anatomy and Embryology, School of Medicine, Institute of Biopathology and Regenerative Medicine (IBIMER), University of Granada Caba O, Ramos J L, Aránega A, Gef gene therapy enhances the therapeutic efficacy of doxorubicin to combat growth of MCF-7 breast cancer cells, Cancer Chemotherapy and Pharmacology, 66 (1), 2010, 69-78.
Shimpo K, Nagatsu T, Yamada K, Sato T, Niimi H, Shamato M, Takeuchi T, Umezawa H, Fujita K, Ascorbic acid and adriamycin toxicity, American Journal of Clinical Nutrition, 54 (6), 1991, 1298-1301.
Venturelli S, Sinnberg T W, Berger A, Noor S, Levesque M P, Böcker A, Niessner H, Lauer U M, Bitzer M, Garbe C, Busch C, Epigenetic Impacts of Ascorbate on Human Metastatic Melanoma Cells, Front Oncol, 4: 227, 2014, 10.3389/fonc.
Verrax J, Calderon P B, The controversial place of vitamin C in cancer treatment, Biochemical pharmacology, 76 (12), 2008, 1644–52.
Vilela- Miranda A L, Grisolia C K, Longo J P, Peixoto R C, de Almeida M C, Barbosa L C, Roll M M, Portilho F A, Estevanato L L, Bocca A L, Báo S N, Lacava Z G, Oil rich in carotenoids instead of vitamins C and E as a better option to reduce doxorubicin-induced damage to normal cells of Ehrlich tumor-bearing mice: hematological, toxicological and histopathological evaluations, The Journal of Nutritional Biochemistry, 25 (11), 2014, 1161- 1176.
It appears that your web browser does not support PDF documents viewing
Discussion
Partners
General partner
Partners
Special thanks
Media partners
Organizer
Passive
Passive
Passive
Passive
Moderator
Passive